Therapeutic Glaucoma

>

Latest News

Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470
Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470

July 20th 2025

Under the terms of the agreement, Kowa receives exclusive rights to develop and commercialize NCX 470 in the US and all other territories of the world excluding Japan, China, Korea, and Southeast Asia.

PolyActiva secures $40 million AUD in Series C funding
PolyActiva secures $40 million AUD in Series C funding

June 14th 2025

(Image credit: AdobeStock/RFBSIP) The impact of preservatives on the ocular surface in patients with ocular hypertension or glaucoma
The impact of preservatives on the ocular surface in patients with ocular hypertension or glaucoma

June 4th 2025

Nicox releases results from Whistler phase 3b trial in IOP-lowering eye drops
Nicox releases results from Whistler phase 3b trial in IOP-lowering eye drops

May 15th 2025

 Santen receives marketing authorization application approval from NMPA of China for tafluprost/timolol maleate (Tapcom) in patients with open-angle glaucoma
Santen receives marketing authorization application approval from NMPA of China for tafluprost/timolol maleate (Tapcom) in patients with open-angle glaucoma

April 7th 2025

Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.